TransCode Therapeutics Publishes TTX-MC138 Research Findings
TransCode Therapeutics announced the publication of preclinical research supporting the application of its lead candidate, TTX-MC138, for the treatment of glioblastoma multiforme. The article was published in the peer-reviewed Journal of Functional Biomaterials. The study, entitled "Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models," resulted from a collaboration between TransCode and Michigan State University. The study was led by Dr. Anna Moore, Professor, Director of the Precision Health Program, and Associate Dean for Research Development at the College of Human Medicine at Michigan State University and scientific co-founder of TransCode. The study demonstrated delivery of TTX-MC138 to human GBM tumors implanted into the brains of murine models after intravenous injection, resulting in sustained target engagement within the tumor. TTX-MC138 also induced apoptotic activity in tumors by five-fold, consistent with observed induction of tumor cell death. Importantly, treatment with TTX-MC138 resulted in a statistically significant increase in survival.
Get Free Real-Time Notifications for Any Stock
Analyst Views on TCMD
About TCMD
About the author
Tactile Systems Technology (TCMD) Shows Strong Growth Potential: Is It a Good Investment?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps identify stocks with strong momentum characteristics, such as Tactile Systems Technology (TCMD), which currently has a score of A.
Tactile Systems Technology Performance: TCMD has shown significant price increases, with an 8.44% rise over the past week and a 93.22% increase over the last quarter, outperforming the S&P 500. The stock also has a Zacks Rank of #2 (Buy), indicating strong potential for future gains.
Earnings Estimates and Trading Volume: Recent upward revisions in earnings estimates for TCMD, along with a consistent average trading volume of 753,286 shares, suggest bullish momentum. The consensus estimate for TCMD has increased from $0.62 to $0.80 in the past 60 days.
Quantum Computing Insights: Quantum computing is rapidly advancing, with major tech companies integrating it into their operations. Senior Stock Strategist Kevin Cook has identified seven stocks that could lead in this emerging field, presenting a unique investment opportunity.
Zacks.com Spotlights Tactile Systems, Canadian Natural Resources, Arlo, and Celestica
Highlighted Stocks: The article discusses four efficient stocks to consider for investment: Tactile Systems Technology (TCMD), Canadian Natural Resources Ltd. (CNQ), Arlo Technologies (ARLO), and Celestica (CLS), all of which have shown strong earnings surprises.
Efficiency Ratios: Key efficiency ratios such as Receivables Turnover, Asset Utilization, Inventory Turnover, and Operating Margin are emphasized as important metrics for evaluating a company's potential to generate profits and manage resources effectively.
